Abstracts Archive - Page 1680 of 2425 - ACR Meeting Abstracts

Abstract Number: 3121 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Patient Reported Outcomes (PROs) in Psoriatic Arthritis
Tawnie Braaten¹, Brian Breviu¹, Jessica Walsh², Angela Presson³, Chong Zhang³ and Daniel Clegg⁴, ¹Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Department of Epidemiology, University of Utah Hospitals and Clinics, Salt Lake City, UT, ⁴Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Gender is an important patient characteristic that may potentially be used to predict clinical presentation, disease progression and therapeutic response. In recent studies, women…
Abstract Number: 3122 • 2015 ACR/ARHP Annual Meeting
A Longitudinal Analysis of Change in Lupus Nephritis in an International Inception Cohort Using a Multistate Markov Model Approach
John G. Hanly¹, Li Su², Murray Urowitz^3,4, Juanita Romero-Diaz⁵, C. Gordon⁶, Sang-Cheol Bae⁷, Sasha R Bernatsky⁸, Ann Clarke⁹, Daniel J Wallace¹⁰, Joan T. Merrill¹¹, David A. Isenberg¹², Anisur Rahman¹³, Ellen M. Ginzler¹⁴, Paul Fortin¹⁵, Dafna D. Gladman¹⁶, Jorge Sanchez-Guerrero¹⁷, Michelle Petri¹⁸, Ian N. Bruce¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Cynthia Aranow²², Graciela S. Alarcon²³, Barri J. Fessler²⁴, Kristján Steinsson²⁵, Ola Nived²⁶, Gunnar K. Sturfelt²⁷, Susan Manzi²⁸, Munther Khamashta²⁹, Ronald F. van Vollenhoven³⁰, Asad Zoma³¹, Guillermo Ruiz-Irastorza³², Manuel Ramos-Casals³³, S. Sam Lim³⁴, Thomas Stoll³⁵, Murat Inanc³⁶, Kenneth C. Kalunian³⁷, Diane L. Kamen³⁸, Peter Maddison³⁹, Christine A. Peschken⁴⁰, Søren Jacobsen⁴¹, Anca Askanase⁴², Chris Theriault⁴³, Kara Thompson⁴³ and Vernon Farewell⁴⁴, ¹Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ²Nova Scotia Rehab Site, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Rheumatology, TWH, Toronto, ON, Canada, ⁴Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁸Division of Rheumatolog, McGill Unversity Health Cener, Montreal, QC, Canada, ⁹Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁰Cedars-Sinai Medical Center, West Hollywood, CA, ¹¹Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ¹³Centre for Rheumatology Research, U College of London, London, United Kingdom, ¹⁴Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, ¹⁵Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, ¹⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁷Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ¹⁸Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ¹⁹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²⁰UNC Kidney Centre, Chapel Hill, NC, ²¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²²Feinstein Institute for Medical Research, Manhasset, NY, ²³Medicine, University of Alabama at Birmingham, Birmingham, AL, ²⁴UAB, Birmingham, AL, ²⁵Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁶Rheumatology, Inst of Clinical sciences, Lund, Sweden, ²⁷Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, ²⁸Rheumatology, Allegheny Health Network, Pittsburgh, PA, ²⁹Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³⁰Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³¹Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ³²Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, ³³Autoimmune Diseases, IDIBAPS, Hospital Clinic, Barcelona, Spain, ³⁴Emory University School of Medicine, Atlanta, GA, ³⁵Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, ³⁶Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁷Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ³⁸Medicine, Medical University of South Carolina, Charleston, SC, ³⁹School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, ⁴⁰Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, ⁴¹Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴²NYU School of Medicine, New York, NY, ⁴³Dept of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁴⁴Medicine, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Patients with lupus nephritis (LN) may have improvement or deterioration in renal status over time. To capture bidirectional change we used a reversible multistate…
Abstract Number: 3123 • 2015 ACR/ARHP Annual Meeting
Evidence of Altered Blood Brain Barrier Permeability in Systemic Lupus Erythematosus Using Magnetic Resonance Imaging
Gaurav Gulati¹, Jordan T. Jones², Mekibib Altaye³, Jamie Meyers Eaton⁴, Kasha Wiley², Mark DiFrancesco⁵ and Hermine I. Brunner⁶, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Biostatistics and Epidemiology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Pediatric Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁵Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Neurocognitive dysfunction is a common manifestation of childhood-onset Systemic Lupus Erythematosus (cSLE). Murine models suggest that loss of the blood-brain barrier (BBB) integrity allows…
Abstract Number: 3124 • 2015 ACR/ARHP Annual Meeting
Associations of Circulating Cell-Free Micro-RNA with Vasculopathy and Vascular Events in SLE Patients
Susan Due Kay¹, Anting L. Carlsen², Anne Voss¹, Mikael Kjær Poulsen³, Axel Cosmus Pyndt Diederichsen⁴ and Niels H. H. Heegaard⁵, ¹Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ²Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark, ³Department of Cardiology, Odense University Hospital, Odense C, Denmark, ⁴Department of Cardiology,, Odense University Hospital, Odense C, Denmark, ⁵Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark
Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs that modulate protein translation and regulate numerous immunologic and inflammatory pathways. Certain miRNA profiles have been associated with…
Abstract Number: 3125 • 2015 ACR/ARHP Annual Meeting
White Matter Magnetization Transfer Ratio Histogram Peak Height Helps Identifying Inflammatory Neuropsychiatric Systemic Lupus Erythematosus
César Magro Checa¹, Ece Ercan², Bart J Emmer³, Ron Wolterbeek⁴, Itamar Ronen², Mark A. Van Buchem², T. W. J. Huizinga⁵ and Gerda M. Steup-Beekman⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Radiology, C.J. Gorter Center for High Field MRI, Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Radiology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Magnetization transfer ratio (MTR) can be used to detect microstructural cerebral changes in normal-appearing brain tissue of neuropsychiatric systemic lupus erythematosus (NPSLE) patients. Our…
Abstract Number: 3126 • 2015 ACR/ARHP Annual Meeting
Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus
Mariana Postal, Aline Tamires Lapa, Karina O. Peliçari, Nailu A. Sinicato, Fernando A. Peres, Angela C. Gomes, Lilian TL Costallat, Fernando Cendes and Simone Appenzeller, Medicine, State University of Campinas, Campinas, Brazil
Background/Purpose: Cytokines and neuronal injury markers act as crucial mediators in the bidirectional signaling between the immune system and the brain and may be biomarkers…
Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting
Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Chaim Putterman¹, D. Scott Batty², I.R. Cohen³, Nicole Jordan⁴, Debbie Rybak¹, Tamar Rubinstein¹, Keren Jakobi⁵, Rachel Sorek⁵, Anat Reiner-Benaim⁵, Yakov Blumenstein⁵ and Pennina Safer⁵, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray Inc., Richmond, VA, ³Weizmann Institute of Science, Rehovot, Israel, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel
Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…
Abstract Number: 3128 • 2015 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis in Blood and Dermal Fibroblasts from Twin Pairs Discordant for Systemic Sclerosis
Paula S. Ramos¹, Thomas A. Medsger Jr.² and Carol A. Feghali-Bostwick¹, ¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The etiology and mechanisms underlying the wide variation in disease heterogeneity and severity in systemic sclerosis (SSc) remain unknown. To assess the role of…
Abstract Number: 3129 • 2015 ACR/ARHP Annual Meeting
Integrative Analysis of the Colonic Microbiota in Systemic Sclerosis
Elizabeth R. Volkmann¹, Yu-Ling Chang², Nashla Barroso³, Daniel E. Furst³, Philip J. Clements¹, Alan Gorn⁴, Bennett Roth³, Jeffrey Conklin³, Terri Getzug³, Maomeng Tong², Jonathan Jacobs³ and Jonathan Braun², ¹Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Pathology and Laboratory Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: Gastrointestinal tract (GIT) dysfunction is a leading cause of morbidity in patients with systemic sclerosis (SSc). However, the etiology of SSc-related lower GIT dysfunction…
Abstract Number: 3130 • 2015 ACR/ARHP Annual Meeting
Epstein-Barr Virus Induces Activation of Infammatory Markers Via the TLR8 Transduction Pathway in Infected Scleroderma Monocytes
Antonella Farina¹, Giovanna Peruzzi^2,3, Valentina Lacconi⁴, Edoardo Rosato⁵, Silvia Quarta⁶, Stefania Morrone¹, Alberto Faggioni¹, Maria Trojanowska⁴ and Giuseppina Alessandra Farina⁴, ¹Department of Experimental Medicine, Sapienza University, Department of Experimental Medicine, Rome, Italy, ²Istituto Italiano di Tecnologia (IIT), CLNS@Sapienza, Rome, Italy, ³Istituto Italiano di Tecnologia (IIT), CLNS@Sapienza, Viale Regina Elena 291, 00161, Rome, Italy, Rome, Italy, ⁴Arthritis Center, Boston University, Arthritis Center, Boston, MA, ⁵Department of Clinical Medicine, Clinical Immunology Unit,, Sapienza University,Department of Clinical Medicine, Rome, Italy, ⁶Department of Clinical Medicine, Clinical Immunology Unit., Sapienza University,Department of Clinical Medicine, Rome, Italy
Background/Purpose: Monocytes from patients with systemic sclerosis (Scleroderma, SSc), are characterized by the increased expression of IFN-regulatory genes, implicating dysregulation of the innate immune response…
Abstract Number: 3131 • 2015 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 7 (IRF7): The Possible Link Between Inflammation and Fibrosis in SSc Pathogenesis
Minghua Wu¹, Gloria Salazar¹, Xiaodong Zhou², Xinjian Guo², John D. Reveille³, Sandeep K. Agarwal⁴, Michael R. Blackburn⁵, Maureen D Mayes¹ and Shervin Assassi¹, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Internal Medicine, University of Texas Medical School at Houston, Houston, TX, ³Internal Medicine/Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁴Internal Med, Rheumatology, Baylor College of Medicine, Houston, TX, ⁵Biochemistry and Molecular Biology, The University of Texas Medical School at Houston, Houston, TX
Background/Purpose: A recent global gene expression profile study in a large early SSc patient samples revealed a type I interferon (IFN) signature. Type I IFN…
Abstract Number: 3132 • 2015 ACR/ARHP Annual Meeting
Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis Via Repressing Pro-Angiogenic Factors
Pei-Suen Tsou^1,2, M. Asif Amin³, Elena Schiopu^2,4, David A. Fox³, Dinesh Khanna^1,2 and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Scleroderma Program, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc) is a complex disease characterized by inflammation, vascular complications, and excessive deposition of extracellular matrix. Vascular dysfunction represents a disease initiating event…
Abstract Number: 3133 • 2015 ACR/ARHP Annual Meeting
The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated By the Urokinase Pathway Via Binding to Enolase-1 and Urokinase Plasminogen Activator Receptor
Tetsuya Nishimoto¹, Takahisa Takihara², Logan Mlakar³, Yunyun Su⁴, Roger Chambers³ and Carol Feghali-Bostwick³, ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Tokai University School of Medicine, Kanagawa, Japan, ³Medical University of South Carolina, Charleston, SC, ⁴Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Fibroproliferative disorders such as systemic sclerosis (SSc) have no effective therapies and result in significant morbidity and mortality. We recently demonstrated that the C-terminal…
Abstract Number: 3134 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Pirfenidone in Patients with Systemic Sclerosis Interstitial Lung Disease
Dinesh Khanna¹, Carlo Albera², Aryeh Fischer³, James R. Seibold⁴, Nader A. Khalidi⁵, Ganesh Raghu⁶, Lorinda Chung⁷, Elena Schiopu¹, Dan Chen⁸ and Eduard Gorina⁹, ¹University of Michigan, Ann Arbor, MI, ²University of Turin, Turin, Italy, ³National Jewish Health and University of Colorado, Denver, CO, ⁴Scleroderma Research Consultants LLC, Litchfield, CT, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Washington, Seattle, WA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸Jazz Pharmaceuticals (formerly of InterMune), Palo Alto, CA, ⁹Formerly of InterMune, Brisbane, CA
Background/Purpose: Interstitial lung disease (ILD) is a common and serious complication of systemic sclerosis (SSc). Pirfenidone, a novel antifibrotic agent, has been shown to be…
Abstract Number: 3135 • 2015 ACR/ARHP Annual Meeting
Incidences and Predictors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal Study
Veronika K. Jaeger¹, Elina G. Wirz^2,3, Yannick Allanore⁴, Gabriela Riemekasten⁵, Eric Hachulla⁶, Oliver Distler⁷, Paolo Airo⁸, Patricia E. Carreira⁹, Alexandra Balbir-Gurman¹⁰, Mohammed Tikly¹¹, Serena Vettori¹², Nemanja Damjanov¹³, Ulf Müller-Ladner¹⁴, Jorg HW. Distler¹⁵, Mangtao Li¹⁶, Ulrich A. Walker¹⁷ and EUSTAR collaborators, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ²Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ³Department of Dermatology, University Hospital Basel, Basel, Switzerland, ⁴Department of Rheumatology A, Paris Descartes University, Cochin Hospital, Paris, France, ⁵Clinic of Rheumatology, University of Luebeck, Lübeck, Germany, ⁶Service de Médecine Interne, Hôpital Huriez, Université de Lille, Lille, France, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁸UO Reumatologia ed Immunologia Clinica, Spedali Civili, Brescia, Italy, ⁹Servicio de Reumatologia, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel, ¹¹Division of Rheumatology, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ¹²Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ¹³Institute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia, ¹⁴Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ¹⁵Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China, ¹⁷Rheumatology, University Hospital, Basel, Basel, Switzerland
Background/Purpose: Systemic sclerosis (SSc) is a rare and clinically heterogeneous autoimmune disorder characterised by fibrosis and microvascular obliteration of the skin and internal organs, particularly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].